Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ERIC 2024 | The new concept of glutamine addiction in CLL and how it may contribute to drug resistance

Eric Eldering • 27 Sep 2024
ERIC 2024
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Eric Eldering, PhD, Amsterdam UMC Cancer Center, Amsterdam, Netherlands, discusses the concept of glutamine addiction in chronic lymphocytic leukemia (CLL). He explains how CLL cells in the lymph nodes become reliant on glutamine for energy and survival, which affects drug resistance. Blocking glutamine import could reduce this resistance and improve treatment outcomes. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Collaboration and/or sponsored research agreements with AstraZeneca, BMS, Genentech, Janssen.

More from Eric Eldering

The role of metabolic programming in CLL biology and the importance of studying lymph node cells 0:54
The role of metabolic programming in CLL biology and the importance of studying lymph node cells
Eric Eldering • 27 Sep 2024

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals